EVCMEverCommerce Inc.
The schedule
- Thu15Oct
A likely fall investor event or major conference appearance would give EverCommerce a platform to detail its vertical product roadmap, particularly around EverHealth Scribe AI and broader workflow automation, and to frame how these initiatives can sustain growth and margin expansion into 2027.
- Sat1May
Q3 2026 earnings will be a critical checkpoint to see whether product initiatives and cost discipline from 2026 have translated into a sustainable growth and margin profile, and whether management can credibly frame a 2027 outlook that supports the stock’s premium valuation.
- Thu29Jul
Past
- Tue4Aug
Actual outcome: Bear
EverCommerce reported Q2 earnings that missed consensus estimates and warned that full-year results are expected to trend toward the lower end of its revenue and adjusted EBITDA guidance ranges due to sluggish demand. This soft outlook, combined with the sudden announcement of a leadership transition replacing founder Eric Remer as CEO, drove the stock down 15.1%.
Q2 2026 earnings will test whether EverCommerce can re-accelerate or at least stabilize revenue after several quarters of contraction, while maintaining profitability and validating the 2026 guidance trajectory under a more challenging rate and SMB demand backdrop.
- Wed15Jul
Actual outcome: Bull · $12.12 at outcome
EverCommerce shares defied the macro risk of a valuation reset, surging 5.4% on heavy volume shortly after the event date. Despite a minor insider sale by the CEO, the stock maintained its upward momentum heading into its Q2 earnings announcement, ultimately exceeding the $10.30 bull target.
Into mid-2026, a potential continuation of the higher-for-longer Fed funds path and tighter financial conditions could drive a de-rating in profitable but slow-growing small-cap software names like EverCommerce, pressuring its elevated multiples even absent company-specific news.
- Thu7May
Actual outcome: Bear · $10.45 at outcome
EverCommerce reported Q1 2026 revenue of $147.5 million, a 3.6% year-over-year increase, and EPS of $0.0338 that exactly met analyst estimates. Despite stabilizing revenues within the expected range, the lack of a meaningful earnings beat or stronger forward guidance failed to satisfy investors. Consequently, the stock fell 11.4% as the market likely sought more robust growth or clearer traction from newer offerings to drive upside.
Q1 2026 earnings will be the first checkpoint after the weak Q4 2025 print and Q1 2026 loss, with investors focused on whether EverCommerce can stabilize revenues around $145–150 million per quarter, sustain positive EPS after the recent $0.0338 result, and reaffirm or tighten 2026 guidance while demonstrating traction from newer offerings like EverHealth Scribe AI.
- Thu12Mar
Actual outcome: Bear · $10.43 at outcome
EverCommerce missed Q4 earnings estimates, reporting $0.03 per share against a $0.04 consensus, which triggered a sharp gap down in the stock price following the release. While the company highlighted the launch of its EverHealth Scribe AI solution, the disappointing financial results and weaker-than-expected quarterly performance drove the stock below the bear floor by the run date.
EverCommerce missed Q4 earnings estimates, reporting $0.03 per share against a $0.04 consensus, which triggered a sharp gap down in the stock price following the release. While the company highlighted the launch of its EverHealth Scribe AI solution, the disappointing financial results and weaker-than-expected quarterly performance drove the stock below the bear floor by the run date.
